Mutations identified during treatment
| . | Nilotinib 300 mg twice daily (n = 282), n . | Nilotinib 400 mg twice daily (n = 281), n . | Imatinib 400 mg once daily (n = 283), n . |
|---|---|---|---|
| Patients with ≥1 postbaseline mutational analysis* | 228 | 215 | 237 |
| Patients with mutations | 11 | 11 | 21 |
| New mutations by Sokal score | |||
| Low | 1 | 2 | 1 |
| Intermediate | 5 | 3 | 8 |
| High | 5 | 6 | 12 |
| Mutation category | |||
| T315I | 3 | 2 | 3 |
| Less sensitive to nilotinib† | 6 | 9 | 4 |
| Other mutations‡ | 2§ | 0 | 14 |
| Multiple mutations | 3 | 2 | 3 |
| Mutations|| | |||
| M244V | 0 | 0 | 4 |
| G250E | 1 | 0 | 2 |
| Q252H | 0 | 1 | 0 |
| Y253H | 4 | 4 | 2 |
| E255K | 1 | 3 | 0 |
| E255V | 0 | 1 | 0 |
| D276G | 0 | 0 | 2 |
| T315I | 3 | 2 | 3 |
| M351T | 0 | 0 | 2 |
| E355G | 0 | 0 | 1 |
| F359C | 0 | 0 | 1 |
| F359I | 0 | 0 | 2 |
| F359V | 4 | 2 | 1 |
| H396R | 0 | 0 | 1 |
| E450G | 0 | 0 | 1 |
| E459K | 1 | 0 | 2 |
| . | Nilotinib 300 mg twice daily (n = 282), n . | Nilotinib 400 mg twice daily (n = 281), n . | Imatinib 400 mg once daily (n = 283), n . |
|---|---|---|---|
| Patients with ≥1 postbaseline mutational analysis* | 228 | 215 | 237 |
| Patients with mutations | 11 | 11 | 21 |
| New mutations by Sokal score | |||
| Low | 1 | 2 | 1 |
| Intermediate | 5 | 3 | 8 |
| High | 5 | 6 | 12 |
| Mutation category | |||
| T315I | 3 | 2 | 3 |
| Less sensitive to nilotinib† | 6 | 9 | 4 |
| Other mutations‡ | 2§ | 0 | 14 |
| Multiple mutations | 3 | 2 | 3 |
| Mutations|| | |||
| M244V | 0 | 0 | 4 |
| G250E | 1 | 0 | 2 |
| Q252H | 0 | 1 | 0 |
| Y253H | 4 | 4 | 2 |
| E255K | 1 | 3 | 0 |
| E255V | 0 | 1 | 0 |
| D276G | 0 | 0 | 2 |
| T315I | 3 | 2 | 3 |
| M351T | 0 | 0 | 2 |
| E355G | 0 | 0 | 1 |
| F359C | 0 | 0 | 1 |
| F359I | 0 | 0 | 2 |
| F359V | 4 | 2 | 1 |
| H396R | 0 | 0 | 1 |
| E450G | 0 | 0 | 1 |
| E459K | 1 | 0 | 2 |
Triggers for postbaseline mutational analysis included mutations or polymorphisms at baseline, lack of response or loss of response on treatment, and end of treatment.
Mutations less sensitive to nilotinib are E255K/V, F359C/V, and Y253H.
Includes imatinib-resistant, nilotinib-sensitive mutations (ie, all mutations except E255K/V, F359C/V, Y253H, and T315I).
Of the 2 nilotinib-treated patients with other mutations, one had an E459K mutation and the other had a G250E mutation.
Individual mutation totals include patients with multiple mutations.